ERS 2019 Day 3 Highlights
Lunchtime Session: Inhaler technology (A joint ERS/Industry session)
ERS 2019 Day 2 Highlights
Hot Topics: New recommendations and priorities for asthma management (A joint GINA/ERS update on asthma)
State of the Art Session: Airway disease (Update on clinical studies)
ERS 2019 Day 1 Highlights
Lunchtime session: An update on COPD (A joint ERS/NEJM session)
Guidelines Session: Severe asthma guidelines (Update on 2019 ERS/ATS guidelines)
Adverse events should be reported. For reporting of adverse events, please write to email@example.com
If you have any questions or comments, please contact us.
Anoro Ellipta, Incruse Ellipta, Relvar Ellipta and Trelegy Ellipta were developed in collaboration with Inc.
©2019 GSK Group of Companies. All rights reserved.
Trademarks are owned by or licensed to the GSK group of companies.
GlaxoSmithKline Pte Ltd, 23 Rochester Park, Singapore 139234, registered in Singapore No. 198102938K
Date of preparation: October 2019